July/August

July 22, 2019

A specialty pharmacy’s specific expertise and experience in supporting patients with cancer is among its most essential attributes.

July 22, 2019

On July 20, 2018, the FDA approved ivosidenib (Tibsovo) as a treatment option for adult patients with relapsed/refractory acute myeloid leukemia, specifically with a mutation in the IDH1 gene.

July 22, 2019

States are getting inventive in their approaches to meeting the health care needs of their citizens, especially when it comes to curative treatments for conditions that have a high prevalence rate.

July 22, 2019

As the deadline for full implementation approaches, hospitals must create an action plan and timeline for completion.

July 22, 2019

Cannabidiol (CBD) has certainly drawn significant attention over the past few months.

July 22, 2019

A strong partnership can support the successful commercialization of a product, position the therapy to meet a manufacturer’s business goals, and provide patients with an option to improve their health and quality of life.

July 22, 2019

Within this evolving new world of health care are the questions surrounding the future of smaller independent pharmacies.

July 22, 2019

Independent specialty pharmacy must see health care cost through a different lens.

July 22, 2019

It is important to promote the ongoing development of best practices for integrated specialty pharmacies in academic health systems.

July 22, 2019

In a Specialty Pharmacy Times® Insights video series, experts Atul A. Deodhar, MD, and Hillary Norton, MD, discussed clinical best practices surrounding the diagnosis, management, and treatment of AxSpA, including an overview of available therapies.

July 22, 2019

Keycentrix, a software and technology company specializing in pharmacy and health care, develops and implements technology solutions with pharmacists in mind.

July 22, 2019

The clinical assessment has long been a cornerstone of patient-centric specialty pharmacy care.

July 22, 2019

With ongoing growth across the board, plan sponsors are continuously searching for ways to minimize the impact on their bottom line.